Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405091 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
NCT02405091 is a Phase 3 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 167 participants.
The verdict
NCT02405091, a Phase 3 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
Study Summary
Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment. This study will enroll approximately 150 medically stable male and female subjects with clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced TD or mood disorder with neuroleptic-induced TD.
Interventions
- DRUG NBI-98854
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02405091
The ClinicalTrials.gov registry entry for NCT02405091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NBI-98854 is the first listed.
NCT02405091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02405091 about?
NCT02405091 is a clinical study titled "Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia". Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment. This study will enroll approximately 150 medically stable male and female subjects with clinical diagnoses of schizophrenia or schizoaffective disorder w...
What is the current status of trial NCT02405091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 2015-03. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02405091?
The interventions under investigation include: NBI-98854 (DRUG).
Who is sponsoring clinical trial NCT02405091?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.